當前位置:BPS Bioscience Inc.>>CAR T-Cell Therapy Cell Lines>> 78772MART-1 TCR (DMF4) CD8+ NFAT-Luciferase Reporter Jurkat Cell Line
Anti-BCMA CAR /NFAT (Luciferase) Re
Anti-CD19 CAR / NFAT (Luciferase) R
This cell line was generated from the T Cell Receptor (TCR) Knockout NFAT Luciferase Reporter Jurkat Cell Line (BPS Bioscience #78556) by overexpression of human CD8 (NM_001768.6) and MART-1-specific TCR (DMF4) using lentiviral transduction (CD8a Lentivirus #78648 and MART-1-Specific TCR Lentivirus Clone DMF4 #78678). The human TCR clone DMF4 specifically recognizes tumor antigen MART-1 (Melanoma-associated antigen recognized by T cells-1, or Melan-A).
Figure 1: Illustration of the functional co-culture assay used to validate the MART-1 TCR (DMF4) CD8+ NFAT-Luciferase Reporter Jurkat cell line.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
請輸入賬號
請輸入密碼
請輸驗證碼
以上信息由企業自行提供,信息內容的真實性、準確性和合法性由相關企業負責,化工儀器網對此不承擔任何保證責任。
溫馨提示:為規避購買風險,建議您在購買產品前務必確認供應商資質及產品質量。